Clinical performance of magnetic resonance imaging and biomarkers for prostate cancer diagnosis in men at high genetic risk

To evaluate different scenarios for the management of early diagnosis of cancer (PCa) in men at high genetic risk, using recently developed blood and urinary molecular biomarkers in combination with clinical information alongside multiparametric magnetic resonance imaging (mpMRI).

[1]  G. Guazzoni,et al.  Prospective evaluation of the role of imaging techniques and TMPRSS2:ERG mutation for the diagnosis of clinically significant prostate cancer , 2022, Frontiers in Oncology.

[2]  J. Ferlay,et al.  Current and projected number of years of life lost due to prostate cancer: A global study , 2022, The Prostate.

[3]  V. Giri,et al.  Germline testing and genetic counselling in prostate cancer , 2022, Nature Reviews Urology.

[4]  J. Hugosson,et al.  Results from 22 years of Followup in the Göteborg Randomized Population-Based Prostate Cancer Screening Trial , 2022, The Journal of urology.

[5]  M. Kattan,et al.  MRI-Detectability of Clinically Significant Prostate Cancer Relates to Oncologic Outcomes After Prostatectomy. , 2022, Clinical genitourinary cancer.

[6]  V. Fasulo,et al.  Re: A Prospective Prostate Cancer Screening Programme for Men with Pathogenic Variants in Mismatch Repair Genes (IMPACT): Initial Results from an International Prospective Study , 2021, European Urology.

[7]  R. Eeles,et al.  A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study , 2021, The Lancet. Oncology.

[8]  O. Parikh,et al.  Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography-The IP1-PROSTAGRAM Study. , 2021, JAMA oncology.

[9]  S. Kaffenberger,et al.  Initial Findings from a High Genetic Risk Prostate Cancer Clinic. , 2021, Urology.

[10]  G. Guazzoni,et al.  The use of 29 MHz transrectal micro-ultrasound to stratify the prostate cancer risk in patients with PI-RADS III lesions at multiparametric MRI: A single institutional analysis. , 2021, Urologic oncology.

[11]  E. Crawford,et al.  Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men , 2021, Prostate Cancer and Prostatic Diseases.

[12]  F. Sanguedolce,et al.  PSA density help to identify patients with elevated PSA due to prostate cancer rather than intraprostatic inflammation: a prospective single-center study , 2020, European Urology Open Science.

[13]  D. Margel,et al.  Imaging-based prostate cancer screening among BRCA mutation carriers-results from the first round of screening. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  D. Nickerson,et al.  8q24 genetic variation and comprehensive haplotypes altering familial risk of prostate cancer , 2020, Nature Communications.

[15]  L. Kiemeney,et al.  Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers , 2019, European urology.

[16]  O. Abdel-Rahman.  Prostate Cancer Incidence and Mortality in Relationship to Family History of Prostate Cancer; Findings From The PLCO Trial. , 2019, Clinical genitourinary cancer.

[17]  John T. Wei,et al.  Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator. , 2019, European urology focus.

[18]  Rhian Gabe,et al.  Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study. , 2018, Health technology assessment.

[19]  F. Hamdy,et al.  Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model: An Individual Patient Data Meta‐Analysis , 2018, The Journal of urology.

[20]  O. Cussenot,et al.  Transition zone and anterior stromal prostate cancers: Evaluation of discriminant location criteria using multiparametric fusion-guided biopsy. , 2018, Diagnostic and interventional imaging.

[21]  I. Schoots.  MRI in early prostate cancer detection: how to manage indeterminate or equivocal PI-RADS 3 lesions? , 2018, Translational andrology and urology.

[22]  Javed Siddiqui,et al.  Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. , 2016, European urology.

[23]  P. Carroll,et al.  Prostate Cancer Early Detection, Version 2.2015 , 2015 .

[24]  B. Delahunt,et al.  The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System , 2015, The American journal of surgical pathology.

[25]  G. Cigliana,et al.  PCA3 in prostate cancer and tumor aggressiveness detection on 407 high-risk patients: a National Cancer Institute experience , 2015, Journal of experimental & clinical cancer research : CR.

[26]  G. Cancel-Tassin,et al.  Accuracy of the prostate health index versus the urinary prostate cancer antigen 3 score to predict overall and significant prostate cancer at initial biopsy , 2015, The Prostate.

[27]  Yair Lotan,et al.  Can urinary PCA3 supplement PSA in the early detection of prostate cancer? , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  T. D. de Reijke,et al.  Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. , 2014, European urology.

[29]  A. Haese*,et al.  Clinical performance of serum prostate‐specific antigen isoform [‐2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project , 2013, BJU international.

[30]  G. Cancel-Tassin,et al.  Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer , 2013, The Prostate.

[31]  H. Parnes,et al.  Prostate cancer specific survival in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. , 2012, Cancer epidemiology.

[32]  R. Eeles,et al.  The role of BRCA1 and BRCA2 in prostate cancer. , 2012, Asian journal of andrology.

[33]  D. Margolis,et al.  PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. , 2016, European urology.

[34]  T. Tammela,et al.  Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up , 2014, The Lancet.